PL1797112T3 - Inhibitory wirusa zapalenia wątroby typu C - Google Patents

Inhibitory wirusa zapalenia wątroby typu C

Info

Publication number
PL1797112T3
PL1797112T3 PL05814026T PL05814026T PL1797112T3 PL 1797112 T3 PL1797112 T3 PL 1797112T3 PL 05814026 T PL05814026 T PL 05814026T PL 05814026 T PL05814026 T PL 05814026T PL 1797112 T3 PL1797112 T3 PL 1797112T3
Authority
PL
Poland
Prior art keywords
virus
hepatitis
present
methods
hepatitits
Prior art date
Application number
PL05814026T
Other languages
English (en)
Inventor
Robert F Garry
Jane A Mckeating
Original Assignee
The Administrators Of The Tulane Educational Fund
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Administrators Of The Tulane Educational Fund, Univ Rockefeller filed Critical The Administrators Of The Tulane Educational Fund
Publication of PL1797112T3 publication Critical patent/PL1797112T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05814026T 2004-09-29 2005-09-26 Inhibitory wirusa zapalenia wątroby typu C PL1797112T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61428004P 2004-09-29 2004-09-29
PCT/US2005/034777 WO2006039326A2 (en) 2004-09-29 2005-09-26 Inhibitors of hepatitits c virus
EP05814026A EP1797112B1 (en) 2004-09-29 2005-09-26 Inhibitors of hepatitits c virus

Publications (1)

Publication Number Publication Date
PL1797112T3 true PL1797112T3 (pl) 2011-04-29

Family

ID=36143015

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05814026T PL1797112T3 (pl) 2004-09-29 2005-09-26 Inhibitory wirusa zapalenia wątroby typu C

Country Status (11)

Country Link
US (2) US7381705B2 (pl)
EP (1) EP1797112B1 (pl)
JP (1) JP4980915B2 (pl)
AT (1) ATE474587T1 (pl)
AU (1) AU2005292135B2 (pl)
CA (1) CA2582095A1 (pl)
DE (1) DE602005022463D1 (pl)
ES (1) ES2349153T3 (pl)
PL (1) PL1797112T3 (pl)
PT (1) PT1797112E (pl)
WO (1) WO2006039326A2 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510122A (ja) * 2005-09-29 2009-03-12 ザ スクリプス リサーチ インスティテュート ウイルスペプチドおよびフラビウイルス科のウイルスに対してウイルス感染を阻害するためのその使用
AP2009005028A0 (en) 2007-04-10 2009-12-31 Univ Tulane Soluble and membrane-anchored forms of lassa virussubunit proteins
US20110097332A1 (en) * 2007-08-06 2011-04-28 Martina Buck Composition and Method of Use for HCV Immunization
WO2009030872A1 (en) * 2007-09-07 2009-03-12 Mats Axel Atterdag Persson Materials and methods for the treatment of hepatitis c
EP2197477B1 (en) * 2007-09-11 2012-04-18 Mondobiotech Laboratories AG Use of lvv-hemorphin-6 and optionally af12198 as therapeutic agent(s)
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
CA2658714A1 (en) 2009-03-17 2010-09-17 Thomas Krey Hcv-derived polypeptides and uses thereof
DK2763696T3 (en) 2011-10-07 2018-10-15 Isd Immunotech Aps Identification of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses
CN104324361A (zh) * 2014-05-16 2015-02-04 中国疾病预防控制中心病毒病预防控制所 丙型肝炎病毒(hcv)细胞进入抑制肽zte2序列及应用
CN109232721B (zh) * 2018-09-26 2021-06-29 广州市第八人民医院 Hcv包膜蛋白高度保守区域的肽段418-429及其用途
CA3148840A1 (en) * 2019-07-26 2021-02-04 The Scripps Research Institute Engineered hcv e2 immunogens and related vaccine compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225068B1 (en) * 1989-03-17 2006-05-29 Chiron Corp Process for producing diagnostics and vaccine of nanbh
US5747239A (en) 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
DK0992580T3 (da) * 1993-11-04 2005-07-11 Innogenetics Nv Epitoper på human T-celler, som er immundominante for hepatitis C-virus
US6127116A (en) 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6037348A (en) 1996-02-09 2000-03-14 Eli Lilly And Company Inhibition of viral replication
CN1268980A (zh) * 1997-03-05 2000-10-04 华盛顿州大学 用于鉴定选择性抑制丙型肝炎病毒复制的试剂的新筛选方法
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
US6127166A (en) * 1997-11-03 2000-10-03 Bayley; Hagan Molluscan ligament polypeptides and genes encoding them
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
EP1178116A1 (en) 2000-08-03 2002-02-06 Hybrigenics S.A. Sid nucleic acids and polypeptides selected from a pathogenic strain of hepatitis C virus and applications thereof
JP5175417B2 (ja) * 2000-08-17 2013-04-03 トリペップ アクチ ボラゲット リバビリンを含むワクチンおよびその使用方法
US20030232745A1 (en) 2001-06-26 2003-12-18 Olson William C. Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection
US7022323B2 (en) 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
WO2004044220A2 (en) 2002-11-08 2004-05-27 The Administrators Of The Tulane Educational Fund Flaviviris fusion inhibitors
EP1638993A4 (en) * 2003-06-10 2007-05-09 Univ Melbourne IMMUNOMODULATING COMPOSITIONS, APPLICATIONS THEREOF AND METHOD FOR THE PRODUCTION THEREOF

Also Published As

Publication number Publication date
EP1797112A4 (en) 2009-04-01
ATE474587T1 (de) 2010-08-15
AU2005292135B2 (en) 2011-09-29
EP1797112B1 (en) 2010-07-21
JP4980915B2 (ja) 2012-07-18
JP2008514717A (ja) 2008-05-08
CA2582095A1 (en) 2006-04-13
WO2006039326A3 (en) 2007-05-10
ES2349153T3 (es) 2010-12-28
AU2005292135A1 (en) 2006-04-13
DE602005022463D1 (de) 2010-09-02
WO2006039326A2 (en) 2006-04-13
PT1797112E (pt) 2010-10-25
US20080241156A1 (en) 2008-10-02
US20060069027A1 (en) 2006-03-30
US7381705B2 (en) 2008-06-03
EP1797112A2 (en) 2007-06-20

Similar Documents

Publication Publication Date Title
PL1797112T3 (pl) Inhibitory wirusa zapalenia wątroby typu C
EA200700243A1 (ru) Способы лечения гепатита с
IS7533A (is) Lifrarbólgu C-veirutálmar
ATE481106T1 (de) Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
EA200900298A1 (ru) Ингибиторы вируса гепатита с
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
EA200801050A1 (ru) Соединения и способы ингибирования репликации вирусного гепатита с
ATE327246T1 (de) Hepatitis c tripeptid inhibitoren
IL192306A0 (en) Anti-viral compounds
ATE413411T1 (de) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
EA200501689A1 (ru) Соединения в качестве ингибиторов вируса гепатита c
EA200900297A1 (ru) Ингибиторы вируса гепатита с
NO20055057L (no) Farmasoytiske blandinger for hepatitt C virale-priteaseinhibitorer
ATE475660T1 (de) Antivirale verbindungen
WO2008103380A3 (en) Hepatitis b virus compositions and methods of use
EP2399575A3 (en) Methods, uses and compositions for treatment of an infection by a virus of the family of flaviviridae through the farnesoid X receptor (FXR) inhibition
EA201170353A1 (ru) Антитела против гепатита с и их применение
WO2009014216A1 (ja) Ｃ型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体およびその用途
WO2005002501A3 (en) Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
WO2004044220A3 (en) Flaviviris fusion inhibitors
Gao et al. HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4+ Th1 cell responses in vivo
DK1417233T3 (da) Humant rekombinant antistof mod det hepatitis C (HCV) ikke-strukturelle NS3-protein, nukleinsyre og anvendelser deraf
ATE521640T1 (de) Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen
TR200202169T1 (tr) Tanı ve tedavide kullanım için pürifiye hepatit C virüsü zarf proteinleri.
ATE409705T1 (de) Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs